Last edition
News about "pancreatic cancer "
US Food and Drug Administration Clears Expanded Access Pathway for Daraxonrasib
Regulator issues “safe to proceed” letter to Revolution Medicines, enabling early patient access to investigational therapy for advanced pancreatic cancer.
Pancreatic Cancer | 04/05/2026 | By News Bureau | 136
Sonire Therapeutics Launches First US Trial of HIFU Therapy for Pancreatic Cancer
Sonire Therapeutics begins US clinical testing of its HIFU platform, aiming to improve outcomes in hard-to-treat pancreatic cancer.
Pancreatic Cancer | 01/05/2026 | By News Bureau
IDEAYA Biosciences Enrolls First Patient in Phase I Trial of IDE892 for MTAP-Deleted Solid Tumours
IDEAYA Biosciences has initiated a Phase I clinical trial of IDE892, a PRMT5 inhibitor, for MTAP-deleted cancers including Non-Small Cell Lung Cancer and Pancreatic Cancer.
Pancreatic Cancer | 11/03/2026 | By News Bureau | 219
SK Biopharmaceuticals Expands Radiopharma Portfolio with New WARF In-Licensing
SK Biopharmaceuticals has in-licensed a second radiopharmaceutical therapy candidate from the Wisconsin Alumni Research Foundation (WARF), further strengthening its pipeline and advancing its strategy to build an integrated, globally competitive radiotherapeutics portfolio.
Pancreatic Cancer | 29/11/2025 | By Dineshwori | 244
Moleculin Launches Grant-Funded Study of Annamycin for Pancreatic Cancer at UNC-Chapel Hill
Moleculin has initiated a grant-funded preclinical programme at the University of North Carolina at Chapel Hill to evaluate Annamycin in pancreatic cancer, including its use alongside novel therapeutic agents and modalities. Early studies suggest Annamycin may effectively target key drivers of the disease.
Pancreatic Cancer | 15/11/2025 | By Dineshwori | 180
Autonomix Secures New European Patent for Catheter-Based Technology
The newly issued ‘298 patent relates to the use of Autonomix’s proprietary technology to collect and process sensing data for real-time physiological monitoring.
Pancreatic Cancer | 22/08/2025 | By Dineshwori | 249
Phanes Therapeutics Earns FDA Fast Track Status for Pancreatic Adenocarcinoma Treatment
Phanes Therapeutics has announced that the US Food and Drug Administration has granted Fast Track designation to PT886 for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma.
Pancreatic Cancer | 21/03/2024 | By Manvi | 1020
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy